Abcam is expected to operate as a standalone operating company and brand within Danaher's Life Sciences segment, furthering Danaher's strategy to help map complex diseases and accelerate the drug discovery process.

Source: https://www.marketscreener.com/quote/stock/ABCAM-PLC-114282616/news/Danaher-to-Acquire-Abcam-44711143/?utm_medium=RSS&utm_content=20230828

Bank of Nova Scotia lifted its stake in Abcam by 0.5% during the fourth quarter.

Source: https://www.etfdailynews.com/2023/09/01/champlain-investment-partners-llc-sells-31730-shares-of-abcam-plc-nasdaqabcm/

BlackRock Inc. increased its position in shares of Abcam by 26.9% during the 1st quarter.

Source: https://www.etfdailynews.com/2023/05/08/abcam-plc-nasdaqabcm-shares-bought-by-td-asset-management-inc/

Finally, State of New Jersey Common Pension Fund D boosted its position in shares of Abcam by 6.4% in the 1st quarter.

Source: https://www.etfdailynews.com/2023/08/06/robeco-institutional-asset-management-b-v-invests-688000-in-abcam-plc-nasdaqabcm/

Milner told The Mail on Sunday that if he manages to block the bid from US conglomerate Danaher, he will list Abcam on the main market of the London Stock Exchange.

Source: https://www.dailymail.co.uk/money/markets/article-12630407/Abcam-founder-speaks-against-growing-exodus-British-life-science-companies.html?ns_mchannel=rss&ns_campaign=1490&ito=1490